Radium-223 is an emitter of high-energy α particles that binds selectively to areas of high bone turnover. In a recently published phase III trial, it prolonged overall survival of patients with symptomatic, castration-resistant prostate cancer with bone metastases and, as a result, has gained FDA approval for this indication.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
Bruland, O. S., Nilsson, S., Fisher, D. R. & Larsen, R. H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12, 6250s–6257s (2006).
Henriksen, G., Breistol, K., Bruland, O. S., Fodstad, O. & Larsen, R. H. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62, 3120–3125 (2002).
Henriksen, G., Fisher, D. R., Roeske, J. C., Bruland, O. S. & Larsen, R. H. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J. Nucl. Med. 44, 252–259 (2003).
Lewington, V. J. Bone-seeking radionuclides for therapy. J. Nucl. Med. 46 (Suppl. 1), 38S–47S (2005).
Liepe, K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr. Opin. Investig. Drugs 10, 1346–1358 (2009).
Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587–594 (2007).
Nilsson, S. et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 48, 678–686 (2012).
Parker, C. C. et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra-223) in patients with bone metastases and castration-resistant prostate cancer. Eur. Urol. 63, 189–197 (2013).
Hafeez, S. & Parker, C. Radium-223 for the treatment of prostate cancer. Expert Opin. Invest. Drugs 22, 379–387 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Grivas, P., Keller, E. Radium-223: a new treatment option for bone-metastatic CRPC. Nat Rev Urol 10, 630–631 (2013). https://doi.org/10.1038/nrurol.2013.232
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.232